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ABSTRACT
Background: The effect of opioids on inflammation and immune responses is an
mportant subject of investigation because immunoregulatory cytokines are produced in
he central nervous system and opioid receptors are widespread in these cells.
Objectives: The aim of this study was to evaluate the immunomodulatory effect
of morphine on the C3 expression (both constitutive and proinflammatory cytokine-
induced C3 expression) in primary rat astrocytes.
Methods: Primary rat astrocytes were untreated or treated with morphine in
different concentrations (10–6 to 10–2 M) before incubation without or with 5 U/mL
tumor necrosis factor- (TNF-), and C3 protein and mRNA expressions were measured.
Similarly, astrocytes were treated with 10–3 M morphine and stimulated with other
roinflammatory cytokines, including 10 ng/mL interleukin-8 (IL-8) and 5 U/mL IL-1.
Astrocytes were exposed to 10–5 M naloxone for 2 hours before adding morphine, and
NF- and C3 protein was measured. Tumor growth factor- (TGF-) was measured
rom the supernatants of each proinflammatory cytokine.
Results: All results are expressed as mean percentages of C3 production by
normalizing C3 without morphine or any cytokine treatment as 100%. Constitutive C3
protein production was decreased at morphine 10–3 M (57.2%) and 10–2 M (30.1%).
retreatment with morphine suppressed induction of C3 expression at both the protein
nd mRNA levels in astrocytes stimulated with TNF-, IL-8, and IL-1 (P  0.05) in
a dose-dependent manner. The inhibition of C3 protein production by morphine (10–3 M;
3%) was partially attenuated by naloxone (52.0%) (P  0.05). The pretreatment of
strocytes with morphine (10–3 M) before stimulation with TNF-, IL-8, and IL-1
increased by 33% (P  0.05), decreased by 15.2% (P  0.05), and did not change the
production of TGF- protein, respectively.
Conclusions: Morphine downregulated both constitutive and proinflammatory
ytokine-induced C3 expression of astrocytes at the transcriptional level, but not in a
ytokine-specific manner. (Curr Ther Res Clin Exp. 2011;72:23-35) © 2011 Elsevier HS
ournals, Inc. All rights reserved.
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Current Therapeutic ResearchINTRODUCTION
The number of recent reports on the broad effects of opioids on the inflammatory
response is growing.1–4 In particular, findings that opioid receptors are present on
the cells of the immune system and that exogenous opioids can suppress immu-
nological activities suggest potential immunoregulatory and/or anti-inflamma-
tory activities of opioids.5–8 Furthermore, the modulation of immune function by
pioids and the implications for susceptibility to infection have been studied
xtensively because these effects may have significant therapeutic consequen-
es.1–4 The effect of morphine, a classic -receptor agonist, on immune function
has been studied closely because of its widespread clinical use compared with
other opioids. Evidence supporting the ability of morphine (in both acute and
long-term treatment) to suppress a variety of immunological end points has been
uncovered.1–4,9–11 The reported inhibitory effects of morphine on innate and
adapted immune responses include alterations in antibody responses, macrophage
and natural killer cell activity, cytokine expression, phagocytic activity, and
more.1,4,9 In addition, there is growing support for the role of morphine on
immune parameters of the central nervous system (CNS), and many investigations
indicate that cells within the brain (neurons and glial cells) express opioid
receptors.10,12–15 Although numerous studies have shown that opioid-induced
immunosuppression can be mediated indirectly through opioid receptors located
within the CNS12–15 or through direct interactions with immunocytes,2 the
precise cellular mechanisms underlying the immunomodulatory effects of opioids
on the CNS require additional investigation.
Considerable evidence supports the potential for glial cells to serve as impor-
tant modulatory neurotropic and neuroimmune elements in the CNS.16–19
Among the glial cells, astrocytes are immunologically competent cells known to
participate in inflammatory events in the CNS by secreting molecules, including
cytokines and complements.17,20 Attempts to elucidate the role of complement in
he physiological and pathological function of the immune system have been
eported previously.21–25 The third component of complement (C3), the most
bundant complement protein in human plasma, is an acute-phase protein that
lays a key initial role in the activation of the inflammatory cascade of the
omplement system.21 However, in the host, uncontrolled activation and syn-
hesis of complement may result in inflammation and tissue damage.25 In the
CNS, there is ample evidence that complement plays a role in demyelination and
inflammation.22,26 For example, the detrimental effects of complement activation
ave been implicated in multiple neuropathological diseases, including Alzhei-
er’s disease, multiple sclerosis, and stroke.22 Recent studies have revealed that
both human and rat astrocytes produce mRNA and protein for many components
of the complement system, and proinflammatory cytokines such as tumor necrosis
factor- (TNF-), interleukin-1 (IL-1), and interferon- (IFN-) are known to
pregulate production of complement factors, including C3 in astrocytes.27–29 Inline with these findings, it is of interest to determine the role of morphine in the
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C.S. Kim et al.modulation of immune functions on C3 production by astrocytes under inflam-
matory conditions.
The aim of this study was to evaluate the immunomodulatory effect of morphine
on both constitutive and proinflammatory cytokine-induced C3 expression in primary
rat astrocytes.
METHODS
This study was approved by the Samsung Bio Research Institute Ethical Committee
on animal research.
Astrocyte Cultures
Primary rat astrocyte cultures were established as described previously.30
Briefly, the brains of 1- to 3-day-old neonatal rats (Sprague-Dawley, Charles
River, Wilmington, Massachusetts) were removed aseptically and placed in ice
cold isolation solution medium (Dulbecco’s modified Eagle’s medium with so-
dium pyruvate and 4.5 mg/mL of glucose, mixed 1/1 (vol/vol) with Ham F-12
medium containing 15 mM HEPES 100 U/mL of penicillin and 100 g/mL of
treptomycin). After removal of the meninges under the dissecting microscope,
he brain tissue was mechanically dissociated by pipetting and passed through 2
equential sievings of nylon mesh (210- and 130-m pore size, respectively). The
cells were pelleted by centrifugation and re-suspended in the culture medium
made from the isolation medium with the addition of 10% fetal bovine serum and
50 U/mL of penicillin and 50 g/mL of streptomycin. Twenty millimeters of cell
uspension at a concentration of 7.5  105 cells/mL was placed in each 75 cm2
tissue culture flask and incubated at 37°C in a humidified atmosphere with 5%
carbon dioxide. The medium was refreshed every 3 days. On day 8, the flasks were
filled with 15 mL of fresh medium, capped tightly, and fastened securely to an
orbital shaker. The flasks were shaken at 250 rpm in a 37°C incubator for 24
hours before the oligodendrocyte-enriched supernatant was removed. The original
flasks received 15 mL of fresh medium and were returned to shake for an
additional 48 hours at 100 rpm to obtain highly purified astrocytes. Astrocytes
isolated using this method are known to be 95% to 97% pure when examined by
immunofluorescent staining for glial fibrillary acidic protein, which is character-
istically produced by these cells. Fluorescence-activated cell-sorting analysis of
these cultures showed that 10% of the cells stain positively with fluorescence
isothiocyanate isomer-conjugated anti-rat CD 11b, a monoclonal antibody that
recognizes the iC3b receptor, which is a cell surface marker of microglia.
C3 Protein Determination by ELISA Technique
C3 protein was identified in the astrocyte culture supernatant using a sandwich
LISA method.29 The 96-well polystyrene plates (Nunc Immunoplate, MaxiSorp,
Thomas Scientific, Swedesboro, New York) were coated with 10 g/mL of goat
immunoglobulin-G (IgG) to rat C3 (Cappel Lab, Durham, North Carolina) for 18
hours at 4°C. All the washings and dilutions were carried out with a solution
containing phosphate buffer, pH 7.4, 0.5 M sodium chloride, 1% bovine serum
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Current Therapeutic Researchalbumin, and 0.1% Triton X-100. The plates were incubated with 1:1000,
1:10,000, 1:50,000, and 1:100,000 diluted normal rat serum or 1:1, 1:2, and 1:4
diluted supernatant for 1 hour at 37°C . After 3 washings, the plates were
incubated with a peroxidase-conjugated goat IgG to rat C3 (1:10,000 dilution)
for 1 hour at 37°C . The reaction was developed with orthophenylenediamine, and
the absorbance was read at 490 nm in an ELISA reader (Dynatech Lab. Inc.,
Alexandria, Virginia). Each plate had controls where the culture supernatant was
replaced with washing buffer. The net absorbance was obtained by subtracting the
average of triplicate controls from the average of triplicate sample values. The
standard curve was generated in each assay with normal rat serum. The detection
limit using this method was 8 ng/mL.
RNA Preparation and Northern Analysis
Astrocyte monolayers were lysed in buffer containing guanidine isothiocyanate and
-mercaptoethanol, and total cellular RNA in lysate was purified by ultracentrifu-
gation through a cesium chloride cushion for 18 hours at 35,000 rpm using a SW 60
Beckman rotor (Beckman Instruments Inc., Palo Alto, California).31 The RNA
amples underwent electrophoresis in a 0.8% agarose-formaldehyde gel, transferred to
itrocellulose paper, and baked for 2 hours at 80°C . Hybridization with specific
DNA probes was carried out in a solution containing 50% formamide, 45%
ybridization buffer (5 somatic stem cell (SSC), 1 Denhardt solution, 0.1% SDS
sodium dodecyl sulfate]),32,33 and 5% denatured herring sperm DNA by incubating
he nitrocellulose paper with phosphorus 32 (32P)-labeled cDNA probes for 48 hours
t 37°C. Radiolabeled probes were prepared by incorporating 32P into the cDNA
fragments using an oligolabeling kit (Pharmacia Fine Chemicals, Piscataway, New
Jersey) according to the manufacturer’s instructions with ()dCTP deoxy-cytidine-
triphosphate-32P (NEN, Boston, Massachusetts). Nitrocellulose papers were washed
equentially with 2 sodium chloride citrate (SCC), 0.1% SDS, and 0.5 SSC, 0.1%
DS, then exposed to X-OMAT AR5 Kodak film (Rochester, NY) at –70°C for
arying periods. The densitometric analysis was performed on a LKB Ultrascan (LKB
nstruments, Bromma, Sweden) using autoradiographs obtained using various expo-
ures. The density ratios of C3 mRNA and glyceraldehyde-3-phosphate dehydroge-
ase (GAPDH) mRNA were used to normalize the C3 mRNA expression.
Effect of Morphine on C3 Protein Expression in Primary Rat
Astrocyte Cells
In preliminary experiments, we examined whether morphine alone had an effect on
3 protein production by primary rat astrocytes. Astrocytes were untreated or treated
ith morphine on a 10-fold scale from 10–6 to 10–2 M for 6 hours. Culture
supernatants were then collected and assayed for C3 protein.
Effect of TNF- on C3 Protein Expression in Primary Rat
Astrocyte Cells
Primary rat astrocytes cells were incubated with 5 U/mL of human recombinant
NF- (R&D System, Minneapolis, Minnesota) at 37°C for 24 hours, and the level of C3
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C.S. Kim et al.protein expression was measured. TNF- (5 U/mL) stimulation for 24 hours resulted in
a 41% increase in C3 protein compared with untreated cells (data not shown).
Effect of Morphine on C3 Protein and mRNA Expression in
Astrocyte Cells Treated with TNF-, IL-8, AND IL-1
To determine whether pretreating primary rat astrocyte cells with morphine would
uppress the ability of TNF- to enhance C3 protein expression, cells were either
ntreated or treated with morphine on a 10-fold scale from 10–6 to 10–2 M for 6
ours before incubation with TNF- 5 U/mL for 24 hours. C3 protein and mRNA
levels were measured. Similar experiments were performed on astrocytes using IL-8
(10 ng/mL), IL-1 (5 U/mL), and morphine 10–3 M.
Effect of Naloxone on Inhibition of C3 Production by Morphine
Primary rat astrocytes cells were treated with naloxone 10–5 M for 2 hours before
adding morphine 10–3 M. Next, 5 U/mL TNF- was added to cells for an additional
24 hours. The amount of C3 protein production was measured. The same experiments
were performed 4 times, and mean data were analyzed.
Transforming Growth Factor- (TGF-) Determination by ELISA
echnique
To determine whether the suppressive effect of morphine on inflammatory cyto-
ine-enhanced C3 production was mediated by the anti-inflammatory cytokine
GF-, astrocytes were pretreated with 10–3 M of morphine for 6 hours and
incubated with TNF-, IL-8, or IL-l for 30 hours. The levels of TGF- proteins in
he corresponding supernatants were assayed by ELISA technique. Identical experi-
ents were performed 3 times, and mean data were used for analysis.
The primary objective of our study was to determine the immunomodulatory effect
f morphine on both constitutive and proinflammatory cytokine-induced C3 produc-
ion. The secondary objective was to determine the role of anti-inflammatory cyto-
ine, TGF-, as the main mechanism of suppressive effect of morphine on proin-
flammatory cytokine-induced C3 production.
Statistical Analysis
The data presented are expressed as mean (SD). The effect of morphine was
nalyzed using the Mann-Whitney U test and Dunnett’s multiple comparison test for
omparison to reference parameter only. In all comparisons, P  0.05 was considered
ignificant.
RESULTS
Effect of Morphine on C3 Protein Expression in Primary Rat
Astrocyte Cells
Results are expressed as mean percentage of C3 production by normalizing con-
titutive C3 as 100%. The addition of morphine to the cell culture for 6 hours
ecreased C3 production (decrease of 56.6% at a morphine concentration of 10–6,57.2% at 10–3 , and 30.1% at 10–2) (Table I).
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Astrocytes Cells Treated with TNF-, IL-8, and IL-1
Results are expressed as mean percentages of C3 production by normalizing C3
nduced by TNF- (5 U/mL) as the reference. At morphine concentrations from 10–6
to 10–4 M, C3 protein levels decreased by approximately 60% of the baseline level,
compared with C3 protein levels measured in astrocytes treated with TNF- alone.
t morphine concentrations 10–3 and 10–2, C3 protein levels decreased by 33.1% and
3%, respectively (Table II). At morphine concentrations 10–3, C3 mRNA level
ecreased to 11.0% (Table III).
Similar results were observed in IL-8 and IL-1 stimulated astrocytes. Results are
xpressed as mean percentages of the baseline C3 production by normalizing C3
nduced by IL-8 (10 ng/mL) and IL-1 (5 U/mL) by 100%. Pretreatment with
morphine (10–3 M) before the addition of IL-8 (10 ng/mL) and IL-1 (5 U/mL) also
ffected the amounts of C3 produced, significantly reducing cytokine-mediated
nhancement in C3 protein levels by 43% and 25%, respectively (P  0.05). The
uppressive effect of morphine pretreatment was also evident on C3-specific mRNA
xpression. C3-specific mRNA density ratios were significantly decreased, with
L-8–mediated enhancement reduced by 20% and IL-1–mediated enhancement
reduced by 22% (Table IV).
Table I. Comparison of C3 production in rat astrocytes treated with incremental dose of
morphine (10–6 to 10–2 M).
Constitutive C3 Level
(untreated with
morphine, baseline)
Morphine
Concentration
(M. –log) 10–6 10–5 10–4 10–3 10–2
100% C3 production (%) 56.6* 95.2 90.7 57.2* 30.1*
Values are expressed as mean percent C3 production.
*P  0.05 compared with baseline.
Table II. Comparison of C3 production in rat astrocytes treated with tumor necrosis
factor- (TNF-) (5 U/mL) and incremental dose of morphine (10–6 to 10–2 M).
C3 Induced by TNF-
Alone as 100%
(baseline)
TNF- (5 U/mL) 
Morphine Concentration
(M. –log) 10–6 10–5 10–4 10–3 10–2
100 C3 production (%) 64* 65* 63* 33* 23*
Values are expressed as mean percent C3 production in rat astrocytes.
*P  0.05 compared with baseline.
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The inhibition of C3 protein production by 10–3 M of morphine (33%) was
partially attenuated by 10–5 M of naloxone (52.0%) compared with C3 levels induced
y TNF- (5 U/mL) alone (considered as reference) (P  0.05) (Table V).
Transforming Growth Factor- Determination
The pretreatment of astrocytes with 10–3 M of morphine before stimulation with
NF-, IL-8 ,and IL-1 increased by 33.3% (P  0.05), decreased by 15.2% (P 
0.05), and did not change the production of TGF- protein, respectively (Table VI).
DISCUSSION
The major emphasis of our study was to investigate the role of morphine on C3
production in astrocytes and to elucidate the molecular mechanisms by which
morphine regulates C3 levels when stimulated by proinflammatory cytokines
(TNF-, IL-8, and IL-1). We observed that morphine downregulated both consti-
tutive C3 and increased expression of the complement component C3 induced by
proinflammatory cytokines TNF-, IL-8, and IL-1 in rat astrocytes.
Table III. Comparison of mRNA density ratio of C3 and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) in rat astrocytes treated with tumor necrosis factor-
(TNF-) and incremental dose of morphine (10–6 to 10–3 M).
TNF- (5 U/mL)
lone (baseline)
TNF- (5 U/mL)  Morphine
Concentration (M. –log) 10–6 10–5 10–3
100 mRNA density ratio of C3 and GAPDH (%) 70* 53* 11*
Values are expressed as mean percent mRNA density ratio of C3 and GAPDH.
*P  0.05 compared with baseline.
Table IV. The percent C3 production and mRNA density ratio of C3 and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) in rat astrocytes treated with proinflam-
matory cytokines (interleukin-8 [IL-8] or IL-1) and morphine.
IL-8 (10 ng/mL) IL-1 (5 U/mL)
C3 production (%)
Proinflammatory cytokine alone 100 100
Treated with morphine 43* 25*
mRNA density ratio of C3 and GAPDH (%)
Proinflammatory cytokine alone 100 100
Treated with morphine 20* 22*
Values are mean percent C3 production and mRNA density ratio of C3 and GAPDH level, respectively.
*P  0.05 compared with baseline.
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as been suggested and several studies have identified opioid receptors on immune
ells.5–8 Moreover, astrocytes have been reported to express -, -, and -opioid
eceptor mRNA at different levels,6 and -receptor has been ascribed to play a central
role in mediating the immunomodulatory effects of opioids on astrocytes of the
CNS.10 In our study, the treatment of rat astrocytes with only morphine, a primary
-agonist, and in different concentrations for 6 hours showed variable suppressive
effects on C3 protein levels. These effects were observed up to morphine concentra-
tions of 10–4, but definite dose-dependent suppression was observed at higher
orphine concentrations (10–3 and 10–2 M). These results demonstrated the potential
for direct suppressive effect of morphine on constitutive expression of C3 in astro-
cytes, especially at higher concentrations.
Generally, inflammatory cytokines such as IL-1, INF-, and TNF- have been
demonstrated to induce the expression of C3 in astrocytes,27–29, but recent studies
have suggested that cytokines can also induce -receptor expressions in both immune
cells and neuronal cells.5,34,35 Ruzicka et al5 investigated the effects of IL-1 on the
levels of opioid receptor mRNAs in rat astrocyte enriched cultures and found that the
Table VI. The changes in tumor growth factor- (TGF-) levels (picogram per milliliter) in
supernatants of cytokine-stimulated rat astrocytes culture untreated and
treated with morphine (10–3 M).
TNF- IL-8 IL-1
TGF- levels,pg/mL
Not treated with morphine 180.1 (40.3) 252.2 (10.3) 141.2 (11.1)
Treated with morphine 241.1 (88.0)* 213.8 (I8.5)† 146.9 (29.9)
IL  interleukin.
Values are mean (SD).
*P  0.05 compared with cells stimulated with TNF- (5 U/mL) only.
Table V. The effect of naloxone (10–5 M) on inhibition of C3 production by morphine
(10–3 M) in rat astrocytes.
TNF- (5 U/ml) Only (baseline)
TNF- (5 U/mL) 
Morphine
(10–3 M)
Naloxone  TNF- (5
U/mL) and Morphine
(10–3 M)
100 C3 production (%) 33* 52†
TNF-  tumor necrosis factor-.
alues are mean percent C3 production.
*P  0.05 compared with cells stimulated with TNF- (5 U/ml) only.
†P  0.05 compared with cells incubated with TNF- (5 U/mL) and morphine (10–3 M).†P  0.05 compared with cells stimulated with IL-8 (10 ng/mL) only.
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ytokines may lead to increased synthesis of opioid receptors, and the subsequently
ncreased morphine binding may provide a molecular basis for greater morphine
odulation of immune function in the inflammatory setting. Our results support this
nding, in that the degree of suppression of C3 protein production was greater when
strocytes were pretreated with morphine (10–3 M) and proinflammatory cytokines
(TNF-; 33%, IL-8; 42%, and IL-1; 25%) compared with the suppression of
onstitutive C3 productions with morphine alone (57%). This finding suggests that
he suppressive effect of morphine might be greater under conditions of inflamma-
ion. In addition, experiments with morphine and TNF- suggest that transcrip-
tional regulation may play a more important role in C3 suppression as there is a
correlation between the reduction of C3 protein and mRNA levels seen in dose-
response studies. Also, similar results were observed with other proinflammatory
cytokines, IL-8 and IL-1, suggesting that the mechanism of morphine-mediated C3
uppression for all 3 cytokines occurs primarily through the impairment of transcrip-
ion of C3 mRNA. In addition, the extent of suppression was not cytokine specific,
n that C3 protein and mRNA levels were reduced by similar degrees for all 3
roinflammatory cytokines.
In our study, naloxone, a specific -receptor antagonist, was used to determine
he role of the -receptor on the inhibition of C3 production by morphine. This
xperiment demonstrated that the inhibition of C3 protein production by mor-
hine (33%) was partially attenuated by 10–5 M naloxone compared with the
level of C3 induced by TNF- alone as (Figure). Although -receptor is known
as the major binding site for morphine, morphine also has good affinity for all 3
types of opioid receptors.9 Thus, it does not appear that morphine acts solely on
Figure. Schematic diagram of modulation of C3 gene expression by morphine and proin-
flammatory cytokines in primary rat astrocytes. N  nucleus; R1  interleukin-1
(IL-1) receptor; R2  IL-8 receptor; R3  TNF- receptor; R4  -receptor; 
excitatory,  inhibitory, ? some genes that would inhibit C3 gene expression.he -receptor. In addition, previous studies have suggested that morphine
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ners.36 Our results also suggest that the effects of morphine on the suppression
of C3 expression was only partially mediated through the -receptor. Additional
studies are warranted to elucidate the role of other opioid receptors on morphine-
mediated immunosuppression.
Morphine has been demonstrated to induce TGF- release from peripheral
lood mononuclear cell cultures.37 TGF- has a potent immunosuppressive effect
and has been shown to inhibit the signaling pathways of inflammatory cytokines,
as well as to reduce C3 production by astroglioma cell lines induced by INF-,
L-, and TNF-.16,27,28 In addition, the suppression of C3 expression by TGF-
occurs in cytokine-specific patterns, with TGF- appearing to play an important
role in regulating C3 production in astrocytes, especially under inflammatory
conditions.16 Our study also measured the level of TGF- to determine whether
morphine stimulated TGF- production, which subsequently led to the suppres-
ion of C3 expression. When astrocytes were pretreated with morphine, the level
f TGF- in supernatants was decreased with exposure to IL-8, increased in the
resence of TNF-, and did not change with IL-1-stimulated astrocytes. In
ddition, the maximum level of TGF- did not exceed 250 pg/mL, which may
not have been sufficient to suppress the proinflammatory cytokine-induced C3
production.19 The marked suppression of C3 production by morphine is unlikely
o be completely dependent on morphine-potentiated release of TGF-.
These results suggest that suppression of both constitutive and proinflammatory
ytokine-induced C3 protein and mRNA expression is mediated at least in part by
pioid receptors on the astrocytes. The complex interaction between opioids and the
mmune system makes it difficult to weigh the impact of each one of these factors in
ntricate pathways of immunosuppression. The clinical implications of these findings
re yet to be determined but it is possible that the use of morphine may potentially
mpact susceptibility to infection.
There are several limitations to this study. First, limitations in study design
nclude using a single concentration of morphine (10–3 M) to determine its
uppressive effects on other proinflammatory cytokines (IL-8, and IL-1). Addi-
tional data on the effects of morphine on IL-8 and IL-1 might have been revealed
by using incremental doses of morphine (10–6 to 10–2 M); however, 10–3 M
morphine was chosen based on our result from the TNF- experiment in which
definite suppression of C3 protein and C3 mRNA was observed, and similarly, a
suppressive effect of morphine pretreatment on IL-8 and IL-1 was observed in
both C3 protein and C3 mRNA expression. Second, different concentrations of
both morphine and naloxone might have revealed more detailed information on
the role of -receptor antagonists on the inhibition of C3 production by mor-
phine. Third, morphine has good affinity for all 3 types of opioid receptors.
Therefore, additional study with pure opioid receptor antagonists is needed to
elucidate the role of other opioid receptors on morphine-mediated immunosup-
pression.
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The results of our study suggest that morphine may downregulate both consti-
tutive and proinflammatory cytokine-induced C3 expression of astrocytes at a
transcriptional level and this downregulation may not occur in a cytokine-specific
manner.
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